ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 154 filers reported holding ARRAY BIOPHARMA INC in Q4 2015. The put-call ratio across all filers is 1.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $4,099,000 | -10.2% | 88,482 | -52.7% | 0.01% | 0.0% |
Q1 2019 | $4,566,000 | +804.2% | 187,257 | +463.0% | 0.01% | +700.0% |
Q3 2018 | $505,000 | -72.1% | 33,259 | -69.1% | 0.00% | -75.0% |
Q2 2018 | $1,808,000 | +134.2% | 107,730 | +127.9% | 0.00% | +100.0% |
Q1 2018 | $772,000 | -76.0% | 47,281 | -81.2% | 0.00% | -80.0% |
Q4 2017 | $3,217,000 | +137.1% | 251,306 | +127.6% | 0.01% | +150.0% |
Q3 2017 | $1,357,000 | +534.1% | 110,397 | +331.5% | 0.00% | +300.0% |
Q2 2017 | $214,000 | +43.6% | 25,585 | +53.2% | 0.00% | 0.0% |
Q1 2017 | $149,000 | -38.2% | 16,700 | -39.0% | 0.00% | 0.0% |
Q4 2016 | $241,000 | -75.8% | 27,396 | -81.4% | 0.00% | -75.0% |
Q3 2016 | $994,000 | +2912.1% | 147,153 | +1202.0% | 0.00% | – |
Q1 2016 | $33,000 | -65.6% | 11,302 | -50.4% | 0.00% | – |
Q4 2015 | $96,000 | -40.7% | 22,800 | -36.0% | 0.00% | -100.0% |
Q3 2015 | $162,000 | +19.1% | 35,627 | -6.8% | 0.00% | 0.0% |
Q3 2014 | $136,000 | -1.4% | 38,219 | +26.2% | 0.00% | -50.0% |
Q2 2014 | $138,000 | – | 30,279 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BVF INC/IL | 9,719,589 | $60,456,000 | 10.40% |
KOPP INVESTMENT ADVISORS LLC | 2,808,537 | $17,470,000 | 6.42% |
Redmile Group, LLC | 3,669,593 | $22,825,000 | 3.44% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,585,406 | $65,841,000 | 3.06% |
QVT Financial LP | 2,878,600 | $17,905,000 | 1.22% |
APEX CAPITAL, LLC | 2,500,000 | $15,550,000 | 1.12% |
FBR & Co. | 113,500 | $706,000 | 1.07% |
Artal Group S.A. | 3,000,000 | $18,660,000 | 0.61% |
Perimeter Capital Partners, LLC | 486,478 | $3,026,000 | 0.56% |
Orbimed Advisors | 4,831,600 | $30,053,000 | 0.54% |